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Abstract
Type I interferons play an important role in the early defense against viral and other pathogens.
These innate responses are also critically important in shaping the subsequent adaptive response.
Thus, a more thorough knowledge of innate response types and mechanisms will improve our
understanding of pathogenesis and guide the development of new therapeutics.
Interferon alpha is used clinically in the treatment of HIV and Hepatitis C infections. The majority
of IFA-α therapies is based on a single IFN-α subtype, IFN-α2. However, IFN-α comprises a
family of multiple subtypes. The biological functions of the distinct subtypes and how they relate
to disease are poorly understood.
The current study developed the tools to distinguish and measure multiple IFN-α subtypes on the
mRNA level in rhesus macaques that are used widely as an important animal model for human
diseases. We were able to identify and measure nine distinct rhesus IFN-α subtypes.
Further, we could demonstrate that in response to oral pathogenic SIV infection, several IFN-α
subtypes are rapidly induced in lymphoid but not at oral and gastrointestinal mucosal surfaces.
While each IFN-α subtype was induced at distinct levels, their relative expression patterns were
identical in all lymphoid tissues examined.
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Introduction
Type I interferons have been known for more than 50 years when it was first discovered that
virally infected cells secrete a substance that prevents the infection of other cells with virus
[1]. We now know that this “substance”, called interferon, in fact is comprised of a mixture
of multiple subtypes that include alpha, beta, omega, kappa, epsilon, tau and zeta interferon.
In humans, IFN-α represents a family of 21 IFN-α subtypes. While some IFN-α genes are
pseudogenes, the majority of them are expressed at the protein level, and all bind to the
same receptor.
The antiviral activity of IFN-α and IFN-β has been extensively studied, but many open
questions remain. Why do multiple IFN-α subtypes exist? What regulates the biological
activity of all the diverse type I interferons when they all bind and signal through the same
receptor? Different pathogens can induce distinct IFN-α subtypes in vitro [2–5], and IFN-α
subtypes can differ in their antiviral activity. However, only few in vivo studies have
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assessed the functional activity of individual IFN-α subtypes and their roles during infection.
Mice expressing an IFN-α1 transgene had significantly lower virus titers after murine CMV
(MCMV) infection than mice transfected with the IFN-α4 or IFN-α9 gene [6]. In another
murine study, acute CMV-induced myocarditis was most efficiently reduced with IFN-α9 or
IFN-β [7]. Murine IFN-α1 was also highly effective in reducing HSV-induced ocular
infection [8]. In contrast, IFN-α1 exerted less antiviral activity in a murine model of
influenza infection when compared to IFN-α5 and IFN-α6 [9]. Recently, it was
demonstrated that IFN-α1, 4 and 9, but not IFN-α6 were able to reduce virus replication in
the murine model of Friends retrovirus infection [10]. How these results translate to human
diseases is unknown.
Current IFN-α based clinical treatments like pegylated interferon (e.g. Pegasys) and
RoferonA, often used to combat Hepatitis C infection, are based on the application of a
single IFN-α subtype, IFN-α2. An exception is the use of Multiferon™. This is despite the
fact that in human patients infected with Hepatitis C, IFN-α5 appears to be the most
prominent IFN-α subtype expressed in the liver [4]. Based on the few, but striking results
demonstrating differences in antiviral activity by various IFN-α subtypes, and considering
the central role of type I interferons in the early immune defense and in directing T and B
cell differentiation, a more comprehensive understanding of IFN-α subtypes in different
disease settings is needed to determine whether distinct IFN-α subtype treatments might be
beneficial in targeting distinct types of infections.
We previously showed that IFN-α mRNA is rapidly induced after oral SIV infection in
infant rhesus macaques [11]. Despite similar high levels of virus replication in lymphoid and
mucosal tissues, we observed significantly higher increases in IFN-α mRNA levels in
lymphoid compared to mucosal tissues [11]. As the early antiviral response at entry sites of
the virus is critically important in the early control of virus replication, a thorough analysis
of the various IFN-α subtypes and their expression patterns in mucosal compared to
lymphoid tissues is warranted.
Therefore, we conducted the study presented here, in which we developed the tools to
distinguish and measure multiple IFN-α subtypes at the mRNA level in rhesus macaques, an
animal species used as a model system for many human diseases. We then determined which
IFN-α subtypes were induced in response to pathogenic SIV infection and/or whether
distinct tissues show unique IFN-α expression patterns.
The results show that following SIV infection of infant rhesus macaques several IFN-α
subtypes are rapidly induced in lymphoid but not at oral and gastrointestinal mucosal
surfaces. While each IFN-α subtype was induced at distinct levels, their relative expression
patterns were identical in all lymphoid tissues examined.
Materials and Methods
Animals and SIV infection
Newborn rhesus macaques (Macaca mulatta) were housed and hand-reared in a primate
nursery in accordance with the regulations of the American Association for Accreditation of
Laboratory Animal Care Standards at the California National Primate Research Center
(CNPRC). Animal procedures were approved by the UC Davis Institutional Animal Use and
Care Committee (IACUC). All animals were born to rhesus macaques of the CNPRC colony
and were negative for HIV-2, SIV, type D retrovirus, and simian T-cell lymphotropic virus
type 1. Six infant macaques were exposed to SIVmac251 (obtained from the CNPRC
Analytical Core) using a previously described repeated oral exposure model [11,12]. The
infected animals were euthanized 3 days after the last SIVmac251 exposure, i.e. day 8 after
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the first virus exposure. The time of euthanasia is subsequently referred to as 1 week post-
infection (p.i.). Six age-matched SIV-naive macaques served as controls.
Tissue collection and cell isolation
At the time of euthanasia, blood, gingiva, tonsil, retropharyngeal and submandibular lymph
nodes (LN), jejunum, colon, mesenteric LN, and axillary LN samples were collected. Tissue
samples were stored in RNAlater (Ambion, Austin, TX) at −20°C until RNA preparation. In
addition, cell suspensions for functional assays were prepared as described [11]. Cell
isolation from intestinal tissues was performed according to previously described methods
[13]. Briefly, ~2 inch pieces of the ileum and colon were rinsed with PBS and then minced
using sterile scalpels. The tissue suspensions were placed in a shaking waterbath in RPMI
1640 containing 7.5% FBS and collagenase type II (0.5 mg/ml) for 30 minutes at 37°C.
After the digestion, the single cell suspension was passed through a 100 μm filter, spun
down and resuspended in 10% FBS in RPMI 1640. The remaining undigested tissue was
resuspended in collagenase-media and the digestion step was repeated a total of 3 times.
Mucosal lymphocytes were then isolated from the obtained single cell suspension by
performing a 35%/60% Percoll (Sigma) gradient centrifugation. Intestinal lymphocytes were
collected from the 35%/60% interface and washed twice with PBS before being resuspended
in 10% FBS in RPMI 1640.
RNA isolation and cDNA preparation
Prior to total RNA isolation, using Trizol (Invitrogen, Grand Island, NY) according to the
manufacturer’s protocol, the tissue samples were homogenized using a Power Homogenizer
(PowerGen 7 mm × 195 mm; Fisher Scientific). RNA was used to determine tissue viral
RNA (vRNA) levels and for gene expression analysis. RNA samples were DNase-treated
with DNA-free (Ambion) for 1 hr. at 37°C. Complementary DNA (cDNA) was prepared
using random hexamer primers (Amersham-Pharmacia Biotech, Inc., Piscataway, NJ) and
M-MLV-Reverse Transcriptase (Invitrogen). Due to the low expression levels of some IFN-
α subtype mRNA levels in tissues of SIV-naïve control animals, cDNA pre-amplification
was performed using the ABI TaqMan Pre-Amp Master Mix Kit (Applied Biosystems,
Foster City, CA) according to the manufacturer’s instructions.
Interferon–α subtype cloning and primer/probe design
At the initiation of the study, the rhesus macaque genome was not fully sequenced.
However, we recently developed a nested PCR strategy to clone the human IFN-α subtypes
[14]. Based on the strategy applied to human IFN-α subtype cloning and the available
sequence information listed on the Baylor College of Medicine Rhesus Macaque Sequencing
Project website, rhesus IFN-α subytpe primers located in the 5′ and 3′ UTR regions were
designed (see Results). The PCR was carried out using the Stratagene Easy A Hi Fidelity
PCR cloning enzyme under the following conditions: 1 min. at 94°C, 30 cycles at 94°C for
15 sec, 55°C for 15 sec, 70°C for 45 sec, followed by 70°C for 5 min. The obtained PCR
products were cloned using Invitrogen’s TOPO TA cloning kit (TOPO TA Cloning® Kit
with One Shot® MAX Efficiency™ DH5α-T1R E. coli). For each IFN-α subtype, a
minimum of three clones were sequenced and compared for sequence homology using
BioEdit Software [15]. Once the sequence was confirmed to be IFN-α subtype specific,
inner primer/probe sets were designed using the previous described criteria for the
amplification of human IFN-α subtypes [14]. The specificity of IFN-α subtype specific
primer-probe sets was confirmed by using 0.01 ng DNA of each cloned IFN-α subtype
(plasmids) for amplification with matched and all non-matched primer/probe sets.
Real-Time (RT) PCR was performed as previously described [11,16]. Briefly, samples were
tested in duplicate, and the RT-PCR for the housekeeping gene GAPDH and the target gene
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from each sample were run in parallel on the same 96 well Optical Plate (Applied
Biosystems, Foster City, CA) in a 25 μl reaction volume containing 5 μl cDNA + 20 μl
Mastermix (Applied Biosystems). All sequences were amplified using the 7900 default
amplification program: 2 min. at 50°C, 10 min. at 95°C, followed by 45 cycles of 15 s at
95°C and 1 min. at 60°C. Results were analyzed with the SDS 7900 system software,
version 2.1. (Applied Biosystems). In this analysis, the Ct value for the housekeeping gene
(GAPDH) was subtracted from the Ct value of the target gene (delta, ΔCt) to normalize for
mRNA input. The average ΔCt value for the tissue sample from all uninfected animals was
then subtracted from the delta Ct value of the corresponding tissue sample from each of the
SIV infected monkey (ΔΔCt). Since the target gene (cytokine) and the reference gene
(GAPDH) are amplified with the same efficiency, and GAPDH values did not differ
depending on the infection status of animals (data not shown), the increase in cytokine
mRNA levels in tissue samples of SIV infected monkeys compared to tissue samples of
uninfected animals could then be calculated as: Increase = 2−ΔΔCt (User Bulletin #2, ABI
Prism 7700 Sequence Detection System (Applied Biosystems).
Immunochistochemistry (IHC) for IFN-α and MxA protein detection
Tissue section slides were stained using the DAKO Autostainer as follows: Formalin-fixed,
paraffin-embedded tissue sections were cleared and rehydrated with xylene (3x), followed
by a graded series of ethanol incubations (100%, 95%, 80%, and 50%), brief rinsing with
water and then with Tris-buffered saline containing Tween 20 (TBST; Dako). For IFN-α
detection, slides underwent antigen retrieval with AR10 (Biogenex, diluted 1:10) in a
pressure cooker, followed by a rinse with water and TBST. Slides for both IFN-α and MxA
detection were blocked with Protein Block (Dako) for 10 minutes, and then incubated in a
humidified chamber with rabbit anti-human IFN-α antibody (US Biological) or mouse anti-
human MxA antibody (kindly provided by Dr. O. Haller, University of Freiburg,
Department of Virology, Germany) for 1 hr. All incubations were done at RT. Slides were
washed with TBST (2x), incubated for 20 minutes with Ready-to-Use Peroxidase
Quenching solution (DAKO) and rinsed with TBST (2x). Next, slides for IFN-α detection
were treated with Advance Link (Dako), and slides for MxA staining with anti-mouse HRP
polymer (Dako) for 15 and 30 minutes, respectively, followed by another wash with TBST
(2x). An additional incubation (15 minutes) with Advance Enzyme (Dako) was performed
for IFN-α detection. Then Substrate-DAB+ (Dako) was added for 10 minutes, slides were
washed with running water for 5 minutes and counterstained with Hematoxylin (Dako) for 5
minutes. Finally, slides were dehydrated with 90% EtOH (3 × 1 minute) and 100% xylene (3
× 2 minutes).
Tissue sections from age-matched SIV-naïve animals were included as negative controls and
tissue sections from SIV-infected animals that had been previously confirmed to be IFN-α
and/or MxA positive served as positive controls.
Slides were examined with a Zeiss Axioskop microscope using Axiovision Software (Zeiss).
Images were acquired at 200x magnification. Relative quantitation of IFN-α or MxA
positive cells per tissue was performed using two different methods. First, tissue sections
were analyzed using Image ProPlus software (Media Cybernetics). Briefly, for each tissue
3–5 images per slides were acquired and analyzed. IFN-α or MxA positive cells showed a
dark brown color compared to IFN-α or MxA negative cells only showing the blue/purple
hematoxylin staining. Then, the T cell area within a lymph node section was outlined, and
based on the assigned color parameters for positive and negative staining, the software
generated area values for positive and negative staining within the determined T cell area.
Thus, a relative assessment of positive and negative staining patterns was obtained, but an
exact quantitation of positive cells per tissue mm2 was not performed. To confirm the
results, IFN-α or MxA positive cells were manually counted in each of the T cell areas
Easlick et al. Page 4













examined (3–5 fields per tissue). Depending on the number of positive cells present per
field, a score was assigned. A score of “1” was assigned when a particular field contained
less than 50 positive IFN-α positive cells, a score of “2” for >50<75, and a score of “3” for
fields with >75 IFN-α positive cells. Microscopic fields with MxA positive cells were
assigned a score of “1” for >3<10 positive cells/field, a score of “2” for >10<25, and a score
of “3” if >25 MxA positive cells were counted. Fields negative for IFN-α or MxA positive
cells were assigned a score of “0”. Both methods resulted in a similar ranking of tissues with
respect to the number of IFN-α and/or MxA positive cells, and therefore only the data from
the latter scoring analysis are reported.
Analysis of pDC frequencies and function
The frequencies and ability of pDC to produce IFN-α were determined essentially as
described previously [17]. Briefly, PBMC or tissue cell suspensions were prepared and
stimulated with HSV-2 for 6 hours at 37°C, 5%CO2. Brefeldin A (10 μg/ml) was added for
the last 5 hours of incubation. After in-vitro stimulation, pDC were analyzed by flow
cytometry. pDC were identified as lineage (CD3, CD20, CD14, CD16) negative, HLA-DR
and CD123 positive. Generally, 300,000 events were acquired on a FACS ARIA. Data were
analyzed with FlowJo (TreeStar, Ashland, OR). Frequencies of pDC were calculated as
percent of mononuclear cells, and frequencies of IFN-α and TNF-α producing cells as
percentage of pDC.
In-vitro PBMC stimulation to determine IFN-α subtype mRNA expression
Rhesus PBMC were purified and stimulated at 1×10^6 cells/ml in RPMI1640 (supplemented
with 10%FBS and penicillin/streptomycin) with HSV-2 (MOI=1), 50 μg of CpG ODN 2336
(InVivoGen) or 10 μg ssRNA40/LyoVec (InVivoGen) for 5 hours. RNA was purified as
described [11,16,18] to determine mRNA levels of the various IFN-α subtypes by RT-PCR.
Virus load measurement
Plasma and tissue RNA samples were analyzed for viral RNA as described previously [11].
Statistical analysis
Results were analyzed using ANOVA One Way Analysis of Variance or the Student t-test
using the GraphPad Prism and InStat software programs, version 4 (Graph Pad Software,
Inc., San Diego, CA). Correlations between two parameters were determined using
regression analysis tools by GraphPad Prism software.
Results
Design of rhesus macaque-specific IFN-α subtype primer-probe sets
Our initial studies were based primarily on the available human IFÑα subtype sequence
information. Assuming that sequences would be highly homologous between humans and
rhesus macaques, we searched the Rhesus Macaque Sequencing Project Website at the
Baylor College of Medicine for sequences with homology to human IFÑα subtypes. Based
on these results, rhesus macaque specific IFÑα subtype sequences were amplified from
rhesus genomic DNA using primer sequences located in the 5′ and 3′ UTR regions (Table
1a, [14]). The obtained PCR products were cloned, and for each expected rhesus IFN-α
subtype, 3 clones were sequenced, aligned to each other and compared to the relevant
human IFN-α subtype sequence. Using this strategy, we generated rhesus macaque specific
clones for 8 out of the 13 known human IFN-α subtypes (IFN-α1/13, IFN–α2, IFÑα4,
IFÑα6, IFÑα8, IFÑα14 and IFÑα21). Rhesus specific clones with sequence homology to
human IFÑα 5, 7, 10, and 16 could not be generated with this initial approach. The clone
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obtained for rhesus IFÑα17 showed a similar degree of nucleotide homology to four human
IFÑα subtype genes (IFÑα4, 7, 10, and 17), and was therefore not considered to represent a
specific rhesus IFÑα subtype. All of obtained rhesus clones span the full coding sequence of
the relative IFN-α subtype gene they encode, when compared to the rhesus IFN-α subtype
gene listed in GenBank (Table 2), except for the IFN-α8 clone that misses the last 25 base
pairs. The sequence homology of each IFN-α subtype clone (beginning from the start codon)
to the coding sequence of the rhesus IFN-α subtype gene in GenBank ranges from 98–100%.
Note that, as in humans, the rhesus macaque sequences for IFÑα1 and IFÑα13 are almost
identical, and therefore were amplified by the same primer sets and are represented by a
single clone.
Coincidentally, while we were pursuing the human [14] and rhesus studies, the rhesus
macaque genome was published [19]. A search of all human IFÑα subtype sequences
against the now annotated rhesus macaque genome database revealed the predicted rhesus
IFÑα17 sequence. This rhesus IFÑα17 sequence was used in the subsequent real-time PCR
assay design. Thus, while there are 13 expressed human IFÑα subtypes, we could identify
and design rhesus-specific molecular assays to distinguish between 9 IFÑα subtypes
(IFÑα1/13, IFÑα2, IFÑα4, IFÑα6, IFÑα8, IFÑα14, IFÑα17, and IFÑα21).
Consistent with our failure to obtain rhesus IFÑα7, IFÑα10 and IFÑα16 clones or
sequences, the human IFÑα7, IFÑα10 and IFÑα16 sequences were most similar to the
predicted sequence for rhesus IFÑα4. In addition, a rhesus counterpart for the human IFÑα5
gene was not found. Instead, the human IFÑα5 sequence appeared to be most closely related
to the predicted sequence for rhesus IFÑα6.
Table 2 presents the summary of the Genbank annotation numbers for the human IFÑα
subtypes, their rhesus counterparts and their nucleotide sequence homology. Sequence
differences for human and rhesus macaque IFN-α subtypes extended to the amino acid level
(Figure 1), thus, demonstrating the divergent evolution of the rhesus macaque and human
IFÑα subtype genes [20].
Next, primer-probe sets for single-round real time PCR amplification for all confirmed
rhesus IFÑα subtype sequences were designed. Towards this goal, previously developed
real-time PCR primer/probe sets for a subset of human IFÑα subtypes (IFÑα1/13, IFÑα2,
IFÑα6 and IFÑα8) [5] were compared to rhesus IFÑα subtype sequences and mismatched
nucleotides between the human and rhesus sequence were optimized for the rhesus specific
sequence (Figure 2, Table 1b and 1c). All other primer-probe sets were designed using the
ABI Primer Design Software. Despite the extensive nucleotide homology between all rhesus
IFÑα subtypes (Figure 2), each subtype-specific primer-probe set preferentially amplified
the unique IFÑα subtype it was matched to (Figure 3A). After confirming the specificity of
the designed rhesus-specific IFÑα subtype primer-probe sets, PCR amplification of all
cloned rhesus IFÑα subtypes was performed over a range from 10 to 1×10^6 copies plasmid
DNA to ensure that all IFÑα subtype sequences were amplified with comparable efficiency.
The similar slopes and the partial overlap of the amplification curves of the various IFÑα
subtypes (Figure 3B) suggest similar efficiency in the PCR amplification.
IFÑα mRNA subtype measurement following in vitro stimulation
To determine the extent to which the various identified rhesus IFÑα subtypes can be
measured with the developed assay, rhesus PBMC were stimulated for 6 hours with either
HSV, a virus that induces strong IFÑα production in human and rhesus PBMC [17,21], the
TLR9 ligand CpG ODN 2236, or the TLR7/8 ligand ssRNA40/LyoVec. The results
demonstrate that multiple IFÑα subtypes can be induced in vitro in rhesus macaque PBMC
(Figure 3C). The magnitude of individual IFÑα subtype mRNA levels was dependent on the
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stimulus type. HSV induced at least 10-fold higher IFÑα subtype mRNA levels compared to
CpG ODN and ssRNA. Generally, IFÑα14, IFÑα17 and IFÑα21 were less induced than
IFÑα1/13, IFÑα2, IFÑα4, IFÑα6, and IFÑα8. Consistent with earlier studies in humans
[14], while the magnitude of induction of the various IFÑα subtypes differed dependent on
the stimulus used, there was no apparent preferential induction of any IFÑα subtype by any
one treatment.
Taken together, these results demonstrated that this highly sensitive and specific assay could
be used to measure the induction of individual IFN-α subtypes in rhesus macaques during
the course of in vivo infection with SIV or other pathogens.
IFÑα subtype expression patterns in lymphoid tissues after oral SIVmac251 infection in
infant macaques
To determine the levels and IFN-a subtype responses to SIV infection in infants, we utilized
available tissue samples from 6 infant macaques that were infected orally at 4 weeks of age
by repeated SIVmac251 inoculation. Of those 6 macaques, all but one animal tested positive
for plasma viral RNA one week after first SIV exposure [11]. The one that tested negative (#
36444) had detectable viral RNA in the submandibular lymph node and the colon (76 and
139 SIV RNA copies per μg tissue RNA, respectively), indicating infection of all 6 SIV-
exposed macaques.
SIV infection resulted in the increase of multiple IFN-α subtypes in various tissues of all
animals (Figure 4 and data not shown). Similar to the in vitro studies (Figure 3C), the
magnitude of mRNA induction differed between the individual IFN-α subtypes with the
highest increases seen for IFÑα1/13, IFÑα2, IFÑα6 and IFÑα8. The relative expression
levels between the various IFÑα subtypes in the different tissues of an individual animal,
however, were remarkably similar. Thus, IFÑα subtypes did not show any tissue-specific
expression patterns in orally SIV-infected infant macaques.
Generally, the overall magnitude of IFÑα subtype induction seemed to be correlated with
the level of virus replication in individual animals. The monkey with the highest plasma SIV
RNA levels (36438) also showed the highest increases in IFÑα mRNA levels for all the
IFÑα subtypes tested (Figure 4A and data not shown). Furthermore, in the tonsil, but not in
the axillary or mesenteric LN, the mRNA expression levels of the most strongly upregulated
IFN-α subtypes, IFÑα 1/13, IFÑα2, IFÑα6, and IFÑα8, positively correlated with the levels
of virus replication in the same tissue (Figure 4B). Consistent with the pattern of virus
dissemination after oral SIV exposure [11], IFÑα subtype mRNA expression levels were
generally highest in the sites closest to the exposure site, i.e. the tonsil, and lowest in the
distant mesenteric LN. In fact, IFÑα mRNA levels of animal 36438 were significantly
higher (P<0.05) in the tonsil compared to the retropharyngeal, the axillary and the
mesenteric lymph node, and the retropharyngeal lymph node had higher gene expression of
all IFÑα subtypes than the mesenteric lymph node (P<0.05).
IFÑα protein production in lymphoid tissues after oral SIV infection
To assess whether IFÑα subtype mRNA expression increases correlated with enhanced
IFÑα protein production, we performed immunohistochemistry in various lymph nodes. The
majority of IFÑα positive cells were localized in the T cell areas of the lymph node (Figure
5A). Relative frequencies of IFÑα positive cells per T cell area for each lymph node
correlated with the IFÑα subtype mRNA expression data. The highest frequencies of IFÑα
positive cells were found predominantly in lymph nodes draining the oral cavity
(retropharyngeal LN) and the tonsil, but less so in the more distal mesenteric LN at one
week after oral SIV exposure (Figures 5A and 5B). The co-localization of an interferon-
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inducible protein, MxA, with IFN-α in the same tissues was evidence that the IFN-α was
biologically active (Figures 5A and 5B). Consistent with low frequencies of IFN-α positive
cells in mesenteric lymph nodes, MxA positive cells were not or only at low frequencies
detectable in the mesenteric lymph nodes (Figure 5). Thus, at the earliest time points post
SIV infection, the expression of MxA is likely related to the total frequencies of IFN-α
secreting cells and to the time IFN-α is present in the tissue to result in the induction of IFN-
α –inducible genes like MxA.
Plasmacytoid dendritic cells as source of IFÑα
Plasmacytoid dendritic cells (pDC) have been identified as the main source of IFN–α during
acute viral infections. To determine whether the increases in IFÑα mRNA and protein were
due to increases in pDC frequencies and/or their activation state, we compared frequencies
in peripheral blood and lymphoid tissues of 4-week old SIV-naïve to SIV-infected infant
macaques at 1 week after SIV exposure using flow cytometry (Figure 6). The submandibular
lymph node is the main draining LN in the oral cavity [22], and indeed, pDC frequencies
were significantly increased in the submandibular and cervical LN of SIV-infected
compared to SIV-naïve animals. For the retropharyngeal LN, a similar trend was observed,
but did not reach statistical significance, likely due to the relatively high animal-to-animal
variation in pDC frequencies. The low cell yields from infant tonsils did not allow the pDC
analysis for tonsils. Importantly though the tissues with the highest numbers of pDC at 1
week after oral SIV infection, e.g. the submandibular and retropharyngeal LN, also showed
the highest increases in IFÑα mRNA levels (Figure 4).
Thus, oral SIV exposure in infant macaques results in (i) the rapid and simultaneous
induction of multiple IFÑα subtypes in various tissues, (ii) the appearance of IFÑα
producing cells in lymph nodes, and (iii) increased pDC frequencies in various lymph nodes
draining the oral cavity. The magnitude of the type I interferon response was highest in the
tonsil and in lymph nodes draining the oral entry site of SIV, thus following the pattern of
virus dissemination.
Mucosal IFÑα responses
In contrast to the strong induction in lymphoid tissues, individual IFÑα subtype mRNA
levels increased only slightly (2- to maximal 6-fold) in the gingiva and the colon (Figure
7A). This is consistent with our previous data generated with a primer/probe set that
preferentially amplified IFÑα2 [11, 18]. This was not due to the induction of type I
interferon genes other than IFN-α. In fact, elevated IFN-β mRNA levels were only observed
in the tonsil, and only in the two animals (36438, 36414) with the highest virus replication
overall (data not shown). Similarly, IFN-κ mRNA levels in the gingiva of SIV-infected
animals were not increased compared to SIV-naïve animals (data not shown), despite the
fact that interferon kappa is preferentially produced by epidermal keratinocytes and can be
induced in the gingiva [23]. Despite our failure to detect a strong induction of any type I
interferon in the mucosa, IRF-7 mRNA levels were strongly expressed in the gingiva and the
colon compared to the controls, and positively correlated with the level of SIV replication in
the same tissue (Figure 7B).
To determine whether the differences in IFÑα induction between lymph nodes and mucosal
sites were due to quantitative or qualitative differences in pDC’s, we compared IFÑα
responses by pDC in cell suspensions from lymphoid and mucosal tissues of 6 months old
macaques after in vitro stimulation with Imiquimod, a TLR7/8 agonist. Consistent with the
ex vivo IFÑα expression analysis, few pDC from the intestinal tissues produced IFÑα
(Figure 7C). TNF-α production by mucosal pDC was also reduced, albeit to a lesser extent.
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Thus, despite the increase of IRF-7 mRNA levels in the gingiva and the colon after SIV
infection, and in contrast to the strong induction of IFÑα subtypes in lymphoid tissues,
mucosal tissues are relatively devoid of IFÑα producing cells during acute SIV infection.
The in-vitro TLR7/8 stimulation studies indicated a lower and/or altered responsiveness of
pDC from intestinal tissues compared to lymph node pDC within an individual animal.
Discussion
Innate responses are critically important in the early control of pathogen replication and
thereby prevention of dissemination from the local entry to distal sites. Innate responses also
determine the nature of the subsequent adaptive response and are involved in the
maintenance of the pathogen-specific response. Therefore, a more detailed knowledge of the
breadth of innate responses will be beneficial in our overall understanding of pathogenesis
and in the design of more efficacious intervention strategies.
Type I interferons have long been known as a first line defense mechanism in viral
infections. In fact, IFÑα is used clinically in the treatment of patients infected with hepatitis
or HIV. However, while IFÑα treatment is successful in some patients, it shows no effect in
others. Multiple factors could contribute to treatment failure [24,25]. Knowing that IFÑα
comprises a family of multiple subtypes, it is imperative that we gain insight into the
regulation and function of these various IFÑα subtypes in human diseases.
The current study developed IFÑα subtype specific primer/probe sets as a means to dissect
the IFÑα response in rhesus macaques (Table 1, Figures 2 and 3). As expected, the rhesus
IFÑα subtype clones revealed a high degree of homology to the human IFÑα subtype genes
(Table 2). Interestingly though, nucleotide alignments between the human and macaque
sequences demonstrated that not all human IFÑα subtypes necessarily correspond to the
same numeric IFÑα subtype in rhesus macaques and vice versa. The comparative analysis
demonstrated that the human sequences for IFÑα7, IFÑα10 and IFÑα16 had no apparent
rhesus gene homologue, but showed a high degree of nucleotide homology to rhesus IFÑα4.
Similarly, we were unable to clone rhesus IFÑα5 and the alignment of the human IFÑα5
sequence against predicted rhesus IFÑα subtype sequences identified rhesus IFÑα6 as
having the highest homology to human IFÑα5. In this context, it is noteworthy that human
IFÑα6 has been proposed to be a pseudogene [26,27]. While we recently showed that IFÑα6
could be induced at low levels after in vitro TLR stimulation in human pDC [14], other
human IFÑα subtypes, including IFÑα5, were induced at much higher levels. In contrast, in
rhesus macaques, IFÑα6, but not IFÑα5, was strongly induced after in vitro TLR
stimulation and in vivo SIV infection. Although one could therefore speculate that the
functional equivalent of human IFÑα5 is rhesus IFÑα6, studies analyzing the genetic
relatedness or divergence of human and rhesus IFÑα subtype sequences were beyond the
scope of this study.
Genetic studies by Woelk et al. have suggested that IFN-α subtype genes in humans and
chimpanzees are closely related [20]. In fact an alignment of all genic and intergenic regions
of each of the IFN-α genes in humans shows the exact same location of the family locus
compared to the chimpanzee IFN-α genes [20]. In contrast, only IFN-α1, IFN-α2, IFN-α8,
IFN-α13 and IFN-α6 are preserved in the locus between humans and rhesus macaques.
Thus, the authors proposed that the most recent common ancestor contained only a subset of
the IFN-α subtype genes, but then the human/chimpanzee and the rhesus IFN-α subtype
genes diverged separately [20]. Both, gene duplication and gene conversion contributed to
the diversity of the IFN-α subytpe genes observed in the different species [20].
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As rhesus macaques are used as model systems for multiple human diseases, it is important
to identify the similarities and differences in immune responses between rhesus monkeys
and humans. In HIV-1 infected patients, increased serum levels of IFÑα have been
associated with disease progression [28,29]. Recently, it was demonstrated that, dependent
on the stage of infection, the expression of IFÑα subtypes in PBMC of HIV-1 infected
patients varies [30], a finding that has potential implications for improved diagnostics and
treatment. The current study in the rhesus macaque model of SIV infection focuses on the
early IFÑα subtype responses as they relate to virus dissemination and anatomic
compartment.
The data demonstrate that multiple IFÑα subtypes are induced in acutely SIV infected infant
macaques (Figure 4). Consistent with IFÑα1 as the first IFÑα subtype induced following
stimulation and necessary for the induction of all other IFÑα subtypes in humans, we
observed a strong increase of IFÑα1/13 mRNA levels in lymphoid tissue of rhesus
macaques at 1 week after SIV infection. A significant increase of IFÑα mRNA levels was
also observed for IFÑα2, IFÑα4, IFÑα6, and IFÑα8. Why gene expression levels were less
elevated for IFN-α14, IFÑα17 and IFÑα21 could not be determined. A recent study showed
that the induction of distinct IFN-α subtypes is regulated by the differential recruitment of
the transcription factors IRF-3 and IRF-7 to the promoter regions of the individual IFN-α
subtype genes [31]. Thus, in future studies, it would be interesting to determine how IRF-3
and IRF-7 expression and activation levels are altered by SIV infection in future studies.
Importantly, if it could be demonstrated that different IFN-α subtypes differ in their anti-SIV
activity, the understanding of regulation of these subtypes would be critical. Similarly, it
would be important to determine whether SIV proteins could induce or inhibit IFN-α
directly. In vitro studies have shown that some HIV-1 proteins, e.g. gp120, can directly
induce IFN-α in human pDC[32]. At the same time, through the recognition of a common
epitope described for HIV-1 gp41and IFN-α, antibodies against IFN-α could interfere with
HIV-1 gp41 binding to cells, and vice versa, HIV gp41-specific antibodies could inhibit
IFN-α function [33,34].
Interestingly though, while the various IFÑα subtypes were induced with different
magnitude, the overall expression pattern was similar in each of the lymphoid tissues tested
in any individual animal. Thus, there was no tissue-specific expression of distinct IFÑα
subtypes and their induction occurred with similar kinetics. Furthermore, we provide
evidence that increased mRNA levels of IFÑα translated into the production of IFÑα protein
and also the production of the IFN-α-inducible protein MxA (Figure 5).
The increased pDC frequencies observed in several lymph nodes close to the virus entry site
at one week after oral SIV exposure, and the established positive correlation between IFÑα
mRNA levels and virus replication in the tonsil, suggested that this early IFÑα response in
infant macaques was predominantly exerted by pDC (Figure 6). This conclusion is
supported by recent studies in adult macaques showing the fast influx of pDC into lymph
nodes in acute SIV infection [35–37] and by demonstrating that the role of pDC in the early
IFÑα response [38]. We cannot exclude the possibility though that differences in IFN-α
production between various tissues could be due to different frequencies of functionally
impaired and/or dying pDC. Studies in SIV infected macaques have shown that pDC
undergo rapid apoptotic cell death after migration into lymph nodes [35].
It is noteworthy that infant macaques had significantly higher frequencies of pDC in lymph
nodes draining the oral cavity compared to pDC frequencies observed in the same tissues of
six adult macaques (data not shown). One could speculate that the exploration of new things
by mouth in infants might result in increased innate effector mechanisms at sites of oral
exposure. In general, in both, infant and adult macaques, pDC frequencies were highest in
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the spleen, followed by lymph nodes draining the oral cavity, and lowest in the mesenteric
lymph nodes and in PBMC (data not shown).
In contrast to lymphoid tissues, mucosal tissues appeared less able to induce potent type I
interferon responses (Figure 7). Although SIV infection induced slightly elevated mRNA
levels for a number of IFÑα subtypes, within an individual animal the magnitude was
considerably lower compared to the increase of IFÑα subtype mRNA levels observed in
lymphoid tissues. Consistent with the low IFÑα subtype mRNA induction in the gingiva and
colon, IFÑα positive cells could rarely be detected by IHC (data not shown).
Assuming that pDC are responsible for the early IFÑα response in SIV infection, pDC
frequencies and/or function must have differed between lymphoid and mucosal tissues of
these animals. In fact, we present in-vitro data demonstrating that TLR stimulation resulted
in lower frequencies of cytokine-producing pDC in intestinal compared to PBMC and lymph
node cell suspensions. This finding is consistent with data obtained in mouse studies [39–
43]. Considering that mucosal sites present the main entry sites for SIV and HIV, future
studies need to address this question more thoroughly by comparing the functional ability of
dendritic cells isolated from effector versus inductive sites within mucosal tissues and
comparing them to dendritic cell function in lymphoid tissues of the same animal.
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Sequence comparison of rhesus macaque and human IFN-α2. Panel A: Nucleotide sequence
alignment of rhesus macaque (underlined) and human IFN-α2. Panel B: Amino acid
alignment of rhesus macaque (underlined) and human IFN-α2. Sequence differences are
indicated by bold italics letters.
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Rhesus macaque IFN-α subtype sequence alignment. Rhesus macaque IFN-α subtype
sequences were aligned using ClustalW2 at www.ebi.ac.uk. Grey shaded regions with star
symbols denote regions of nucleotide homology between all rhesus IFN-α subtypes. The
forward and reverse primer sequences are indicated in bold black and italic letters,
respectively, while probe sequences are in underlined.
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Specificity and amplification of rhesus macaque IFN-α subtype primer/probe sets. Panel A:
Specificity of the rhesus macaque IFN-α subtype primer/probe sets tested by PCR using
IFN–α subtype-specific cDNA clones. Shown are Ct values for amplification of each
distinct rhesus IFN-α subtype cDNA clone by each of the various IFN-α subtype primer/
probe sets. Shaded boxes indicate IFN-α subtype specific amplification of the relevant IFN-
α subtype cDNA clone. Panel B: PCR efficiency of rhesus IFN-α subtype amplification.
Shown are the Ct values per input copy number for each of the IFN-α subtype cDNA clones.
Amplification was linear for all rhesus IFN-α subtypes over the tested range from 10 to 10^6
copies. Panel C: IFN-α subtype induction in rhesus PBMC. Rhesus PBMC were stimulated
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with HSV, CpG ODN or ssRNA for 6 hours and then mRNA levels for various rhesus IFN-
α subtypes were determined by real time PCR. Shown are the relative increases for each
IFN-α subtype mRNA in comparison to the mRNA level of the same IFN-α subtype in
medium control cultures. One representative example out of 3 experiments is shown.
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IFN-α subtype mRNA levels in tissues at 1 week after oral SIV infection. Panel A: The
relative increase in IFN-α subtype mRNA levels in tissues of infant macaques at 1 week
after oral SIV exposure in comparison to average IFN-α subtypes in the same tissues of age-
matched infant macaques are shown. Shown are the data for the animals with the lowest
(#36443) and highest level (#36438) of SIV replication in plasma and tissues. The x-axis
denotes the IFN-α subtype and virus replication (copies per μg total tissue RNA). The
different tissues are indicated by different colors (tonsil-filled red bars, retropharyngeal LN-
empty red bars, mesenteric LN- blue bars, axillary LN- grey bars). Panel B: Relationship
between SIV RNA and IFN-α subtype mRNA expression levels in the tonsil of SIV-infected
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infant macaques. The SIV replication levels, expressed as SIV RNA copies/μg tonsil RNA,
of all six infant macaques are plotted against the log10 increase in IFN-α subtype mRNA
levels in the tonsil. A positive relationship between SIV replication and distinct IFN-α
subtype mRNA levels is indicated by red lines.The table below the figure lists the P and
Spearman R values for the correlation, and the P and R2 values for the linear regression
analysis between SIV replication and IFN-α subtype mRNA levels.
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Detection of IFN-α positive cells by IHC. Panel A: IFN-α (Images 1, 3, 5, and 7) and MxA
(Images 2, 4, 6, and 8) positive cells (Magnification: 20x). Images 1 and 2 show IFN-α and
MxA staining in retropharyngeal LN of SIV-negative age-matched infants (negative
control). IFN-α and MxA positive cells of SIV-infected infants in the retropharyngeal lymph
node (Images 3, 4), the axillary (Images 5, 6) and the mesenteric LN (Images 7, 8) show a
brown staining pattern. Panel B: Relative frequencies of IFN-α and MxA positive cells. The
individual scores of the relative frequencies of IFN-α and MxA positive cells in each
analyzed microscopic field within the T cell area in the tissues of SIV-negative and SIV-
infected infants. The scores were determined as described in Materials and Methods.
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Frequencies of pDC in tissues of infant macaques. Panel A shows the gating strategies
applied to the flow cytometric analysis. The percentage of pDC among mononuclear cells
isolated from various tissues of 1 SIV-infected (n=6, filled bars) and age-matched SIV-naive
(n=6, empty bars) infant macaques is shown in Panel B. Statistically significant differences
between SIV-naïve and SIV-infected infants in specific tissues are indicated by P values.
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IFN-α responses in mucosal tissues. Panel A shows the relative increases in IFN-α subtype
mRNA levels in the gingiva (left panel) and colon (right panel) of SIV-infected infants
compared to IFN-α mRNA levels of SIV-naïve infants. Panel B demonstrates the
relationship between tissue SIV RNA levels and relative log10 increases in IRF-7 mRNA
levels in the gingiva (left panel) and colon (right panel) of the same SIV-infected infant
macaques. Panel C shows the frequencies of IFN-α and TNF-α producing pDC in lymphoid
and mucosal tissues after in –vitro stimulation with Imiquimod. Cell suspensions from
tissues of SIV-naïve, 6-month old macaques were stimulated for 6 hours with Imiquimod
and then analyzed for the frequencies of IFN-α (left panel) and TNF-α (right panel)
producing pDC using multiparameter flow cytometry. Note that frequencies were lower in
the colon and ileum compared to cell suspensions prepared from lymph nodes. The two bars
per tissue are representative of two different animals.
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Table 1a
PCR primer sequences for the Cloning of Rhesus IFN-α Subtypes









Note: Lower case letters indicate that sequences differ from the human cloning primers by Szubin et al., 2008
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Table 1b
Real Time PCR Primer-Probe Sets for IFN-α Subtype Amplification
Gene Forward primer (5′-3′) Reverse primer (5′-3′) Probe (5′-3′)
IFN-α1/13 CTTCAACCTCTTTACCACAAAAGAcTC TGCTGGTAGAGTTCAGcGCA TGCTTGGGATGAGGACCTCCTAGACA
IFN-α2 CTTGAAGGACAGACATGACTTTGGA GGATGGTTTGAGCCTTTTGGA TTCCCCAGGAGGAGTTTGGCAACC
IFN-α4 TCCTGCCTGAAGGACAGgCAT TGGATCATCTCATGGaGGA ACTTTGCATTCCCCCAGGAGGA
IFN-α6 TCCATGAGGTGATTCAGCAGAC GCTGCTGGTAAAGTTCAGTATAGAGTTT CTGTTGCTTGGGATGAGAGGCTTCTAGAC
IFN-α8 CCTTCTAGATGAATTCTACATCGAACTTG ACTCTATCACCCCCACTTCCTG CAGCTGAATGACCTGGAGTCCTGTGTG
IFN-α14 GCCCTGGTGGTGCTTAGCTA TGTGCCATGAGCATCAAAGTC AGTCAAGCTGCTCTCTGGGCTG
IFN-α17 TCTGGGCTGTGATCCTCCC TCCTTCAGACAGGAGAAAGGAGAGTT TCCTTGATACTCCTGGCACAAATGGGAA
IFN-α21 ACAAGGCTCAAGCCATCTCT AGGATGCAGTCCACATTCGT TACAGGAGGTTGGAGTGGAAGAGACT
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Table 1c
Location of Rhesus IFN-α Subtype Primers and Probes within their respective Rhesus Gene
Gene Genbank No Forward Primer Sequence Location Reverse Primer Sequence Location Probe Sequence Location
IFN-α1/13 XM001099165 132–158 196–215 165–190
IFN-α2 XM001107516 225–247 (1) 277–297 (1) 250–273
IFN-α4 XM001107635 293–313 378–396 315–336
IFN-α6 XM001099374 272–293 352–379 323–351
IFN-α8 XM001107458 352–380 416–437 (2) 386–412
IFN-α14 XM001107576 85–113 164–184 116–127
IFN-α17 XM001107999 205–223 280–306 251–278
IFN-α21 XM001108051 356–375 544–563 512–537
(1) Number in parentheses represent the number of mismatches between the primer or probe sequence and the actual gene sequence
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